MeiraGTx (MGTX) said Wednesday that the US Food and Drug Administration has granted its AAV8-RK-RetGC program rare pediatric disease designation for treating Leber congenital amaurosis caused by GUCY2D mutations (LCA1).
The company said it has received this fourth rare pediatric disease designation in the past three months, following similar designations for treatments targeting LCA4 retinal dystrophy, Bardet-Biedl syndrome, and RDH12-associated retinal dystrophy.
The designation is given to drugs for rare diseases affecting fewer than 200,000 patients, primarily those under 18. If a company gains approval for a treatment for a rare pediatric disease, it may receive a voucher for priority review of a future application, the company added.
Price: 6.13, Change: -0.28, Percent Change: -4.37
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。